Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi Sales, Profit Beat Forecasts
03:25am, Thursday, 25'th Apr 2024
Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new d
Sanofi Q1 profit slips on generic competition, forex effects
01:32am, Thursday, 25'th Apr 2024
Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflam
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
10:21am, Wednesday, 24'th Apr 2024
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
01:06pm, Tuesday, 23'rd Apr 2024
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
FTC looking to accelerate inquiry into prescription-drug middlemen, chair says
01:06pm, Tuesday, 23'rd Apr 2024
The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can ke
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
07:09pm, Tuesday, 16'th Apr 2024
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
11:42am, Tuesday, 09'th Apr 2024
The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts
10:08am, Monday, 08'th Apr 2024
Sanofi (NASDAQ: SNY ) layoffs are in the news Monday after the therapeutic solutions company announced changes to how it will handle research and development going forward. Sanofi wants to focus mor
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
07:12am, Thursday, 04'th Apr 2024
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
05:33pm, Wednesday, 03'rd Apr 2024
Sanofi has reached an agreement in principle to settle 4,000 lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.
Sanofi: My Top Pick In Big Pharma
02:07am, Monday, 25'th Mar 2024
Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and num
Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings
02:52pm, Wednesday, 13'th Mar 2024
While the U.S. is the best block in the neighborhood, sometimes, the area could get a little crowded, which then may offer an opportunity for global growth stocks. No one's saying to avoid American se
Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript)
02:29pm, Tuesday, 12'th Mar 2024
Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript)
Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows
02:00pm, Thursday, 07'th Mar 2024
AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro
3 Cash Cow Dividend Stocks for Outsized Income & Upside
05:51pm, Tuesday, 27'th Feb 2024
Following another shaky day in the market, investors may want to consider cash cow dividend stocks. They're not sexy and they probably won't make you rich.
